TcLand Expression Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$6.18M
- Investors
-
1
TcLand Expression General Information
Description
Developer of biomarkers intended to treat unmet medical needs. The company is engaged in the development of immune profiling and gene expression biomarkers for kidney transplantation and auto-immune disorder, enabling healthcare professionals to help in treatments for patients.
Contact Information
Website
www.tcland-expression.com
Formerly Known As
TcLand
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- 35 Rue du Fort
- 68330 Huningue
- France
TcLand Expression Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 23-Dec-2014 | $6.18M | Completed | Generating Revenue | ||
| 4. Merger/Acquisition | 01-Jul-2013 | 000.00 | Completed | Generating Revenue | ||
| 3. Later Stage VC | 17-Jun-2011 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 2. Grant | 01-Jun-2010 | $563K | $12.1M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 14-Dec-2007 | $12.1M | $12.1M | Completed | Startup |
TcLand Expression Patents
TcLand Expression Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2668287-B1 | Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody | Active | 25-Jan-2011 | 0000000000 | 0 |
| EP-2668287-A2 | Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs | Active | 25-Jan-2011 | 0000000000 | |
| US-20150240304-A1 | Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs | Inactive | 25-Jan-2011 | 0000000000 | |
| CA-2793137-A1 | Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) | Inactive | 24-Mar-2010 | 0000000000 | |
| EP-3211097-A1 | Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) | Inactive | 24-Mar-2010 | C12Q1/6809 | 0 |
TcLand Expression Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
TcLand Expression Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Auriga Partners (Paris) | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Debiopharm Innovation Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| European Regional Development Fund (Brandenburg) | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
| L'Agence Nationale de la Recherche | Government | 000 0000 | 000000 0 | ||
| OSEO Innovation | Venture Capital | Minority | 000 0000 | 000000 0 |